China Pharma Holdings, Inc
China Pharma Holdings, Inc. is a Nevada holding company whose operating business is conducted in China through its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. Helpson develops, manufactures, and markets prescription pharmaceutical products for human use, with a focus on high-incidence and high-mortality diseases prevalent in the PRC. Its portfolio includes dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company sells substantially all of its products through local GSP-certified drug distributors, which then supply state-owned hospitals. China Pharma’s business is shaped by Chinese healthcare distribution practices, regulatory approvals from the NMPA, and working-capital pressure from long collection cycles.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrescription drugs used to treat infectious and respiratory conditions sold through Chinese distributors and hospitals.
Products used for central nervous system and cardiovascular indications, including injectable therapies.
Products such as omeprazole used for digestive and gastrointestinal conditions.
Smaller product lines not included in the core therapeutic categories disclosed by management.
Customers
The company primarily sells to local drug distributors in China rather than directly to hospitals or patients. These distributors are typically GSP-certified and act as the channel through which products reach state-owned hospitals, which are the end-use buyers in the Chinese healthcare system. China Pharma’s customer base is therefore shaped by the hospital procurement process, regulatory logistics requirements, and the payment behavior of public hospitals. The company also appears dependent on a relatively small number of channel customers, which increases concentration and credit exposure. Because payment is often delayed until hospitals pay distributors, customer quality is closely tied to receivables collection and bad-debt risk.
Primary buyers that purchase from Helpson and resell into the hospital channel; they buy because they are licensed to handle pharmaceutical circulation and are the practical route to market.
End-market users that ultimately consume the products and drive distributor demand; they buy prescription medicines for inpatient and outpatient treatment.
Institutional demand base for approved medicines used in common disease areas, especially where procurement is centralized or hospital-led.
Regional pharmaceutical intermediaries that distribute approved products and support market access in China.
Strategy
China Pharma’s near-term strategy appears centered on maintaining access to working capital, preserving distributor relationships, and supporting the launch of new products. Management highlights bank lines of credit, CEO advances, and a convertible note as important liquidity sources, which suggests financing is a core strategic priority rather than a side issue. The company also emphasizes product development and commercialization, but its ability to execute is constrained by going-concern risk and limited cash resources. In parallel, it is managing receivables, inventory, and credit losses to keep the distribution model functioning in a delayed-payment environment. Longer term, the company’s competitive position depends on sustaining NMPA-approved products and adapting to centralized procurement pressure in China.
The company needs external funding to support operations and avoid disruption given limited cash and going-concern pressure.
New products can reduce dependence on a few therapeutic categories and support revenue growth in a competitive market.
Long distributor payment cycles and receivable write-offs make cash conversion a key determinant of business continuity.
Geography
China is the company’s only meaningful operating geography, because all operations are conducted through Helpson in the PRC. Manufacturing facilities are located in China, and the company’s products are sold into the Chinese pharmaceutical market. The business is exposed to PRC regulatory controls, including NMPA approvals, GSP distribution standards, and foreign-exchange restrictions on RMB conversion and remittance. Management also notes that cash held in the Chinese subsidiary is considered reinvested indefinitely and may not be readily available to the U.S. parent. This makes the company highly dependent on Chinese operating conditions, healthcare policy, and capital controls.
Risks
The most immediate risk is liquidity and going-concern pressure, because the company relies on external financing, CEO support, and bank credit to fund operations. Credit risk is also material: the business sells through distributors that often wait for payment from state-owned hospitals, creating long collection cycles and exposure to bad debts. The company is exposed to Chinese healthcare policy changes, including centralized procurement and NMPA logistics requirements, which can shift product demand and pricing. Foreign-exchange and capital-control restrictions in the PRC may limit the parent company’s ability to access cash generated by the subsidiary. More generally, the company faces pharmaceutical industry risks such as regulatory approvals, product concentration, pricing pressure, and inventory obsolescence.
Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing.
Customers are distributors paid after state-owned hospitals settle, which creates long collection periods and write-off risk.
NMPA rules, GSP requirements, and centralized procurement can alter market access, pricing, and product mix.
RMB conversion and remittance restrictions may limit the parent’s access to cash held in China.
Accounting
Judgemental itemsThe company estimates collectability for distributor receivables and records bad-debt expense or credit based on allowance changes.
Impact: Can materially affect operating results and net receivables
Management wrote off accounts receivable aged over eight years, showing that historical balances can be removed in large blocks.
Impact: Can create significant one-time charges and reduce assets
Pharmaceutical inventory is exposed to procurement changes, market volatility, and potential obsolescence.
Impact: Can affect cost of goods sold and gross margin
Cash and operations are primarily denominated in RMB, and PRC controls may limit remittance to the U.S. parent.
Impact: Affects liquidity analysis and parent-level cash access
Similar listed companies
Publicly listed companies with a comparable business focus.
China SXT Pharmaceuticals, Inc.
SXTC · Pharmaceutical Preparations
Universe Pharmaceuticals INC
UPC · Pharmaceutical Preparations
Universe Pharmaceuticals INC is a Cayman Islands holding company headquartered in Ji'an, Jiangxi, China, that operates through subsidiaries in Hong Kong and mainland China.
China Foods Holdings Ltd.
CFOO · Medicinal Chemicals & Botanical Products
Concord Medical Services Holdings Ltd
CCM · Services-Offices & Clinics of Doctors of Medicine
Concord Medical Services Holdings Ltd is a medical services group headquartered in Beijing, with operations centered on hospital, clinic, and other healthcare service assets in China.
111, Inc.
YI · Retail-Drug Stores and Proprietary Stores
Waterdrop Inc.
WDH · Insurance Agents, Brokers & Service
Last updated: 11/08/2026